THRIVE-2 met all primary and secondary endpoints at the 15-week primary analysis timepoint after 5 infusions of veligrotug.

Shares of Viridian Therapeutics surged nearly 18% at the open on Monday to a nearly three-week high after the company ...

Viridian Therapeutics advances promising therapies for thyroid eye disease. See why VRDN stock stands to benefit from a ...

The company’s chronic thyroid eye disease treatment, veligrotug, was able to reduce eye bulge by 56% compared with placebo.

The Lancet Diabetes & Endocrinology Commission on Diagnostic Criteria of Clinical Obesity will soon unveil a new ...

Findings showed the proptosis responder rate at week 15 was ... 3 THRIVE-2 study evaluating veligrotug in patients with chronic thyroid eye disease (TED). Veligrotug is an investigational ...

In an interview with Ophthalmology Times, Alon Kahana, MD, PhD, discusses interleukin-6 and its role in autoimmune diseases, particularly thyroid eye disease, noting that a promising alternative under ...

JMP Securities analyst Jason Butler has reiterated their bullish stance on VRDN stock, giving a Buy rating today.Pick the best stocks and ...

Viridian Therapeutics (VRDN) announced topline data from the THRIVE-2 phase 3 clinical trial of veligrotug, an intravenously delivered anti-insulin-like growth factor-1 receptor antibody, in patients ...

Viridian (VRDN) shares shot up 25% after the company reported positive results from a Phase 3 study of veligrotug in the ...

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced positive ...

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye ... achieving a week 15 proptosis responder rate ...